The solution may still appear clear, but its potency could be reduced by an unknown amount
The math is straightforward, and the results are predictable
The key is to keep changes simple and doable, so they stick
Moving from insulin to GLP-1 A patient on basal insulin whose Type 2 diabetes is relatively well controlled might transition to a GLP-1 agonist if they are gaining excessive weight on insulin, want to simplify their regimen, have developed cardiovascular risk factors that would benefit from GLP-1 protection, or have adequate remaining beta cell function
It is a genuine needle-free option with efficacy evidence, not the same as compounded oral peptide tablets, which have no published human absorption data
Contact Pure Med Spa Chicago to schedule your consultation